Across the recent three months, 7 analysts have shared their insights on Corcept Therapeutics CORT, expressing a variety of opinions spanning from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 5 | 2 | 0 | 0 | 0 |
| Last 30D | 1 | 0 | 0 | 0 | 0 |
| 1M Ago | 1 | 1 | 0 | 0 | 0 |
| 2M Ago | 0 | 0 | 0 | 0 | 0 |
| 3M Ago | 3 | 1 | 0 | 0 | 0 |
In the assessment of 12-month price targets, analysts unveil insights for Corcept Therapeutics, presenting an average target of $60.29, a high estimate of $80.00, and a low estimate of $38.00. This current average reflects an increase of 41.16% from the previous average price target of $42.71.
Interpreting Analyst Ratings: A Closer Look
In examining recent analyst actions, we gain insights into how financial experts perceive Corcept Therapeutics. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
| Analyst | Analyst Firm | Action Taken | Rating | Current Price Target | Prior Price Target |
|---|---|---|---|---|---|
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $80.00 | $45.00 |
| Joon Lee | Truist Securities | Raises | Buy | $76.00 | $65.00 |
| David Amsellem | Piper Sandler | Raises | Overweight | $67.00 | $38.00 |
| Edward Nash | Canaccord Genuity | Raises | Buy | $78.00 | $38.00 |
| Edward Nash | Canaccord Genuity | Maintains | Buy | $38.00 | $38.00 |
| David Amsellem | Piper Sandler | Raises | Overweight | $38.00 | $35.00 |
| Swayampakula Ramakanth | HC Wainwright & Co. | Raises | Buy | $45.00 | $40.00 |
Key Insights:
- Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Corcept Therapeutics. This information offers a snapshot of how analysts perceive the current state of the company.
- Rating: Offering insights into predictions, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Corcept Therapeutics compared to the broader market.
- Price Targets: Analysts predict movements in price targets, offering estimates for Corcept Therapeutics's future value. Examining the current and prior targets offers insights into analysts' evolving expectations.
Capture valuable insights into Corcept Therapeutics's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
Stay up to date on Corcept Therapeutics analyst ratings.
About Corcept Therapeutics
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Financial Insights: Corcept Therapeutics
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Corcept Therapeutics's remarkable performance in 3 months is evident. As of 30 June, 2024, the company achieved an impressive revenue growth rate of 39.15%. This signifies a substantial increase in the company's top-line earnings. As compared to its peers, the company achieved a growth rate higher than the average among peers in Health Care sector.
Net Margin: Corcept Therapeutics's net margin excels beyond industry benchmarks, reaching 21.44%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): Corcept Therapeutics's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 6.14%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): Corcept Therapeutics's ROA excels beyond industry benchmarks, reaching 5.13%. This signifies efficient management of assets and strong financial health.
Debt Management: Corcept Therapeutics's debt-to-equity ratio is below the industry average at 0.01, reflecting a lower dependency on debt financing and a more conservative financial approach.
The Significance of Analyst Ratings Explained
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
Beyond their standard evaluations, some analysts contribute predictions for metrics like growth estimates, earnings, and revenue, furnishing investors with additional guidance. Users of analyst ratings should be mindful that this specialized advice is shaped by human perspectives and may be subject to variability.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. Click here for urgent details.
This article was generated by Benzinga's automated content engine and reviewed by an editor.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
|---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
